Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Liver Transplantation

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 89 articles: HTML format

Single Articles

April 2025
1. MOORE LW, Brombosz EW, Ghobrial RM
   To Sleeve or Not to Sleeve: Validation of Liver Transplantation with Sleeve Gastrectomy.
   J Hepatol. 2025 Apr 15:S0168-8278(25)00242-9. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
2. BURKE L, Bernal W, Pirani T, Agarwal B, et al
   Plasma exchange does not improve overall survival in patients with acute liver failure in a real-world cohort.
   J Hepatol. 2025;82:615-621.
   PubMed     Abstract available
   
   
   March 2025
3. HUWYLER F, Pfister M, Binz J, Tibbitt MW, et al
   Benefits of multi-day ex situ perfusion include dampened ischemia reperfusion injury in liver transplantation.
   J Hepatol. 2025 Mar 25:S0168-8278(25)00208-9. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
4. LARSON EL, Ellias SD, Blezek DJ, Klug J, et al
   Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis.
   J Hepatol. 2025 Mar 13:S0168-8278(25)00139-4. doi: 10.1016/j.jhep.2025.
   PubMed     Abstract available
   
   
   
5. ARTRU F, Ursic-Bedoya J, L'Hermite S, Saliba F, et al
   Reply to : "Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries ?".
   J Hepatol. 2025 Mar 5:S0168-8278(25)00133-3. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
6. EDEN J, Thorne AM, Bodewes SB, Patrono D, et al
   Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study.
   J Hepatol. 2025;82:523-534.
   PubMed     Abstract available
   
   
   February 2025
7. HE K, Chen L, Xia Q
   Is MELD-Cr an Accurate Predictor of Liver Transplant Outcomes? A Call for Refinement in Allocation Criteria.
   J Hepatol. 2025 Feb 20:S0168-8278(25)00095-9. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
8. ROSENSTENGLE C, Serper M, Asrani SK, Bittermann T, et al
   Variation in intention-to-treat survival by MELD subtypes: All models created for end-stage liver disease are not equal.
   J Hepatol. 2025;82:268-276.
   PubMed     Abstract available
   
   
   January 2025
9. MISHRA AK
   Long-term outcome following liver transplantation of patients with ACLF grade 3 : Need of redefining boundaries?
   J Hepatol. 2025 Jan 23:S0168-8278(25)00024-8. doi: 10.1016/j.jhep.2025.
   PubMed    
   
   
   
10. ACEITUNO L, Gravely AK, O'Kane GM, Vogel A, et al
    The use of immunotherapy pre-liver transplant.
    J Hepatol. 2025 Jan 3:S0168-8278(24)02702-8. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
11. REZAEE-ZAVAREH MS, Yeo YH, Wang T, Guo Z, et al
    Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    J Hepatol. 2025;82:107-119.
    PubMed     Abstract available
    
    
    
12. EDEN J, Bruggenwirth IMA, Berlakovich G, Buchholz BM, et al
    Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study).
    J Hepatol. 2025;82:97-106.
    PubMed     Abstract available
    
    
    December 2024
13. 
    EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.
    J Hepatol. 2024 Dec 16:S0168-8278(24)02508-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    November 2024
14. DE GOEIJ FHC, Wehrle CJ, Abassi F, Satish S, et al
    Mastering the Narrative: Precision Reporting of Risk and Outcomes in Liver Transplantation.
    J Hepatol. 2024 Nov 16:S0168-8278(24)02713-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    October 2024
15. SAMUEL D
    EASL Clinical Practice Guidelines on liver transplantation.
    J Hepatol. 2024 Oct 23:S0168-8278(24)02440-1. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
16. PARENTE A, Wehrle CJ, Schold JD, Panconesi R, et al
    Reply to: "Trends in current use of machine perfusion for donation after cardiac death donors in the US".
    J Hepatol. 2024;81:e189-e191.
    PubMed    
    
    
    
17. MATEVISH LE, Vagefi PA, Patel MS
    Trends in current use of machine perfusion for donation after cardiac death donors in the US.
    J Hepatol. 2024;81:e187-e188.
    PubMed    
    
    
    September 2024
18. REZAEE-ZAVAREH MS, Guo Z, Yang JD
    Addressing the Complexities of Pre-Liver Transplant Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Response to Recent Commentaries.
    J Hepatol. 2024 Sep 19:S0168-8278(24)02558-3. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
19. TABRIZIAN P, Holzner M, Ajmera V, Kim AK, et al
    Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study.
    J Hepatol. 2024 Sep 8:S0168-8278(24)02541-8. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
20. ALLEN E, Taylor R, Gimson A, Thorburn D, et al
    Transplant benefit-based offering of deceased donor livers in the United Kingdom.
    J Hepatol. 2024;81:471-478.
    PubMed     Abstract available
    
    
    August 2024
21. MAGAZ M, Giudicelli-Lett H, G Abraldes J, Nicoara-Farcau O, et al
    Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02481-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
22. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    PubMed     Abstract available
    
    
    July 2024
23. VAN LEEUWEN LL, Irizar H, Kim-Schluger L, Florman S, et al
    The Potential of Machine Learning to Predict Early Allograft Dysfunction after Normothermic Machine Perfusion in Liver transplantation.
    J Hepatol. 2024 Jul 31:S0168-8278(24)02438-3. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
24. HAO L, Shan D, Xue J
    Strategic Timing and Patient Selection for ICIs Prior to Liver Transplantation for HCC.
    J Hepatol. 2024 Jul 27:S0168-8278(24)02432-2. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
25. ARTRU F, Sacleux SC, Ursic-Bedoya J, Ntandja Wandji LC, et al
    Long-term outcome following liver transplantation of patients with ACLF grade 3.
    J Hepatol. 2024 Jul 7:S0168-8278(24)02346-8. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    June 2024
26. FUSTER-ANGLADA C, Mauro E, Ferrer-Fabrega J, Caballol B, et al
    Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.
    J Hepatol. 2024 Jun 24:S0168-8278(24)02324-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
27. ESSER H, Kilpatrick AM, Man TY, Aird R, et al
    Primary cilia as a targetable node between biliary injury, senescence and regeneration in liver transplantation.
    J Hepatol. 2024 Jun 13:S0168-8278(24)02302-X. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
28. HE T, Sun K, Zou J
    Biomarker predictors and LRT strategies for HCC recurrence post-liver transplantation: A comment.
    J Hepatol. 2024 Jun 6:S0168-8278(24)00422-7. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
29. LI M, Bhoori S, Mehta N, Mazzaferro V, et al
    Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    J Hepatol. 2024 Jun 5:S0168-8278(24)00423-9. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
30. NORMAN JS, Mehta N
    Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
    J Hepatol. 2024;80:e273-e274.
    PubMed    
    
    
    May 2024
31. CHICHELNITSKIY E, Goldschmidt I, Ruhl L, Rubsamen N, et al
    Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00367-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
32. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
33. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Reply to: "Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding".
    J Hepatol. 2024 May 15:S0168-8278(24)00346-5. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
34. GAMBELLA A, Salvi M, Molinari F
    Response to: Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 May 15:S0168-8278(24)00350-7. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
35. MULLER X, Rossignol G, Boulanger N, Mohkam K, et al
    In situ or ex situ split: Does it all come down to static cold storage?
    J Hepatol. 2024;80:e210-e211.
    PubMed    
    
    
    March 2024
36. LI Y, Yang F, Liu K
    Application of Digital Pathology in Liver Transplantation.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00207-1. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
37. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
38. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    PubMed     Abstract available
    
    
    February 2024
39. MARTIN-MATEOS R, Martinez-Arenas L, Carvalho-Gomes A, Aceituno L, et al
    Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors.
    J Hepatol. 2024 Feb 28:S0168-8278(24)00128-4. doi: 10.1016/j.jhep.2024.
    PubMed     Abstract available
    
    
    
40. DE VILLE DE GOYET J
    Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
    J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
41. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    January 2024
42. LAUTERIO A, Cillo U, De Carlis R, Bernasconi D, et al
    Reply to: "Outcome of in-situ split liver transplantation in Italy over the last 25 years: an alternative analysis and personal view".
    J Hepatol. 2024 Jan 25:S0168-8278(24)00057-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
43. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    December 2023
44. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
45. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period.
    J Hepatol. 2023 Dec 18:S0168-8278(23)05308-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
46. SMEETS JJH, van Malenstein H, van der Merwe S, Nevens F, et al
    SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05362-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
47. PARENTE A, Jiao C, Eden J, Dutkowski P, et al
    machine perfusion, randomized controlled trials, liver transplantation, immune cellsPerfusate immune cell profiling during machine perfusion - A new tool to link risk and immune response after liver transplantation?
    J Hepatol. 2023 Dec 16:S0168-8278(23)05364-3. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
48. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
49. DE CARLIS R, Lauterio A, Bernasconi D, Taner B, et al
    Reply to: "Excellent long-term outcomes after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation": Further comments on the changing role of donor warm
    J Hepatol. 2023;79:e245-e247.
    PubMed    
    
    
    November 2023
50. PARENTE A, Dondossola D, Dutkowski P, Schlegel A, et al
    Current evidence on the beneficial HOPE-effect based on systematic reviews and meta-analyses in liver transplantation.
    J Hepatol. 2023 Nov 10:S0168-8278(23)05233-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
51. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    October 2023
52. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
53. DE VILLE DE GOYET J
    Outcome of in-situ split liver transplantation in Italy over the last 25 years : an alternative analysis and personal view.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05151-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
54. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    September 2023
55. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
56. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
57. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
58. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    PubMed     Abstract available
    
    
    
59. EDEN J, Dutkowski P, Schlegel A
    Reply to: "How many liver grafts could be recovered after implementation of donation after cardiac death in Germany?".
    J Hepatol. 2023;79:e120-e121.
    PubMed    
    
    
    
60. EDEN J, von Felten S, Dutkowski P, Schlegel A, et al
    Reply to: "A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation".
    J Hepatol. 2023;79:e116-e118.
    PubMed    
    
    
    
61. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    PubMed     Abstract available
    
    
    
62. HAKEEM AR, Taylor R, Prasad R
    Comment on "Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicentre analysis of the US, the UK, and Canada".
    J Hepatol. 2023;79:e112-e114.
    PubMed    
    
    
    
63. CZIGANY Z, Michalski CW
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;79:e114-e116.
    PubMed    
    
    
    August 2023
64. TANG G, Zhang L, Zhou R
    Letter to the Editor: Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05045-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
65. 
    EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    PubMed     Abstract available
    
    
    
66. KARTOUN U
    Fairness metrics: Additional principles to consider for improving MELD.
    J Hepatol. 2023;79:e80-e81.
    PubMed    
    
    
    July 2023
67. VAN LEEUWEN OB, Bodewes SB, Porte RJ, de Meijer VE, et al
    Excellent long-term outcome after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05004-3. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
68. LAUTERIO A, Cillo U, Spada M, Trapani S, et al
    Improving outcomes of in situ split liver transplantation in Italy over the last 25 years.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04988-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    June 2023
69. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
70. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
71. PARENTE A, Tirotta F, Pini A, Eden J, et al
    Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00399-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
72. KAPLAN A, Korenjak M, Brown RS Jr
    Post-liver transplantation patient experience.
    J Hepatol. 2023;78:1234-1244.
    PubMed     Abstract available
    
    
    
73. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    PubMed     Abstract available
    
    
    
74. MONTANO-LOZA AJ, Rodriguez-Peralvarez ML, Pageaux GP, Sanchez-Fueyo A, et al
    Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
    J Hepatol. 2023;78:1199-1215.
    PubMed     Abstract available
    
    
    
75. DE CARLIS R, Paolo Muiesan, Taner B
    Donation after circulatory death: Novel strategies to improve the liver transplant outcome.
    J Hepatol. 2023;78:1169-1180.
    PubMed     Abstract available
    
    
    
76. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    PubMed     Abstract available
    
    
    
77. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    PubMed     Abstract available
    
    
    
78. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    PubMed     Abstract available
    
    
    
79. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    PubMed     Abstract available
    
    
    
80. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    PubMed    
    
    
    
81. SCHLEGEL A, Mergental H, Fondevila C, Porte RJ, et al
    Machine perfusion of the liver and bioengineering.
    J Hepatol. 2023;78:1181-1198.
    PubMed     Abstract available
    
    
    
82. TANER T, Hilscher MB, Broda CR, Drenth JPH, et al
    Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: Current practices and immunological aspects.
    J Hepatol. 2023;78:1157-1168.
    PubMed     Abstract available
    
    
    
83. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    PubMed     Abstract available
    
    
    May 2023
84. EDEN J, Sousa Da Silva R, Cortes-Cerisuelo M, Croome K, et al
    Utilization of livers donated after circulatory death for transplantation - An international comparison.
    J Hepatol. 2023;78:1007-1016.
    PubMed     Abstract available
    
    
    April 2023
85. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
86. SCHLEGEL A, Mueller M, Muller X, Eden J, et al
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;78:783-793.
    PubMed     Abstract available
    
    
    March 2023
87. MOOSBURNER S, Sauer IM, Weiss B, Pratschke J, et al
    How many liver transplantations could be recovered after implementation of donation after cardiac death in Germany?
    J Hepatol. 2023 Mar 11:S0168-8278(23)00176-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
88. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    PubMed    
    
    
    
89. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Transplantation is free of charge.